¿Qué aporta prosigna en el tratamiento adyuvante de pacientes con cáncer de mama? - page 16

Risk groups – ROR score
HR (95% CI)
Low (N=1183 (55.4%))
-
Intermediate (N=538 (25.2%))
3.26 (2.07-5.13)
High (N=416 (19.5%))
6.90 (4.54-10.47)
2.4%
16.6%
8.3%
0
5
10
15
20
5
6
7
8
9
10
Follow-up time [years]
Low
Intermediate
High
Distant recurrence
(%)
0
5
10
15
20
1...,6,7,8,9,10,11,12,13,14,15 17,18,19,20,21,22,23,24
Powered by FlippingBook